FDA buys time

WASHINGTON - FDA announced that it will answer "on or before July 28" the various citizens petitions that have been filed in conjunction with the dispute over the agency's classification of Molecular Biosystems Inc.'s FS069 ultrasound contrast agent as a device (see BioCentury April 28). The response will address petitions and comments submitted on behalf of MB (San Diego, Calif.) and its opposition